Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies

Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline in symptomatic Alzheimer’s disease (AD). Although regulatory approval of this approach is still pending, preparing the he...

Full description

Saved in:
Bibliographic Details
Published in:Molecular psychiatry 2021-01, Vol.26 (1), p.296-308
Main Authors: Zetterberg, Henrik, Bendlin, Barbara B.
Format: Article
Language:English
Subjects:
59/57
59/78
692/53/2421
692/699/476
82/1
82/56
Alzheimer Disease - drug therapy
Alzheimer Disease - metabolism
Alzheimer's disease
Amyloid
Amyloid beta-Peptides - metabolism
Behavioral Sciences
Biological markers
Biological Psychology
Biomarkers
Biomarkers - metabolism
Cognitive ability
Cognitive Dysfunction - drug therapy
Cognitive Dysfunction - metabolism
Development and progression
Drug development
Drug therapy
Expert Review
Health aspects
Humans
Inflammation
Medicine
Medicine & Public Health
Neurodegeneration
Neurodegenerative diseases
Neurosciences
Neurovetenskaper
Pharmacotherapy
Physiological aspects
Plaque, Amyloid - drug therapy
Plaque, Amyloid - metabolism
Psychiatric research
Psychiatry
Regulatory approval
Senile plaques
Tau protein
tau Proteins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline in symptomatic Alzheimer’s disease (AD). Although regulatory approval of this approach is still pending, preparing the healthcare system for the advent of disease-modifying therapies against AD is imperative. In particular, it will be necessary to identify the most suitable biomarkers to facilitate appropriate treatment of AD. Here, we give an update on recent developments in fluid and imaging biomarkers for AD-related pathologies and discuss potential approaches that could be adopted to screen for and clarify the underlying pathology in people seeking medical advice because of cognitive symptoms. We succinctly review recent data regarding biomarkers for Aβ and tau pathology, neurodegeneration, synaptic dysfunction, and inflammation, highlight the need for further research into common copathologies, and suggest how different biomarkers could be used (most likely in combination) to facilitate the development and clinical implementation of novel drug candidates against AD.
ISSN:1359-4184
1476-5578
1476-5578
DOI:10.1038/s41380-020-0721-9